Telix Pharmaceuticals Limited (TLX)
Automate Your Wheel Strategy on TLX
With Tiblio's Option Bot, you can configure your own wheel strategy including TLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLX
- Rev/Share 2.3646
- Book/Share 1.7155
- PB 10.2434
- Debt/Equity 1.0233
- CurrentRatio 2.7759
- ROIC 0.0606
- MktCap 5946489423.2598
- FreeCF/Share 0.0272
- PFCF 660.9414
- PE 116.5977
- Debt/Assets 0.3834
- DivYield 0
- ROE 0.1027
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLX | H.C. Wainwright | -- | Buy | -- | $23 | July 3, 2025 |
| Initiation | TLX | Wedbush | -- | Outperform | -- | $22 | June 5, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC. Telix's revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about certain of its drug candidates and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
Published: July 31, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $TLX--TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC. Telix's revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about certain of its drug candidates and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
Telix H1 2025 Results: Investor Webcast Notification
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.
Read More
Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
TLX boasts a diverse pipeline and strong sales growth, especially with Illuccix and Gozellix, supporting my continued confidence in their theranostics approach. Financials remain robust, with year-over-year revenue growth and no cash runway concerns, aided by expanding product approvals in the EU and new launches. An SEC subpoena has led to substantial concerns from the market, but it is unclear what this pertains to at this time.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: July 24, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TELIX PHARMACEUTICALS LIMITED (TLX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What H.
Read More
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting.
Read More
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET.
Read More
Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
Published: April 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix® sales and RLS Radiopharmacies acquisition.
Read More
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Telix Shares May Gain on the Distribution Deal With Cardinal Health
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Read More
About Telix Pharmaceuticals Limited (TLX)
- IPO Date 2024-11-14
- Website https://telixpharma.com
- Industry Biotechnology
- CEO Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, MBA
- Employees None